Cellular and molecular mechanisms of action of bisphosphonates

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2961-2978

  Rogers, Michael J ^a   Gordon, S ^a   Benford, H L ^a   Coxon, F P ^a   Luckman, S P ^a   Monkkonen, J ^b   Frith, J C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; ATP; Bisphosphonates; Bone resorption; Mevalonate; Osteoblast; Osteoclast; Prenylation

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; EB 1053; ETIDRONIC ACID; GUANOSINE TRIPHOSPHATASE; IBANDRONIC ACID; INCADRONIC ACID; MEDRONIC ACID; MEVALONIC ACID; NE 58051; NE 97220; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PROTEIN TYROSINE PHOSPHATASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE MINERAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HYPERCALCEMIA; METABOLIC BONE DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0034659773     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l     Document Type: Conference Paper

References (119)

1. Russell RGG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 1970;2:899-902.
2. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973;11:269-80.
3. Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978;54:265-8.
4. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.
5. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
6. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia. Bone 1995;16:235-45.
7. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-90.
8. Ebetino FH, Francis MD, Rogers MJ, Russell RGG. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother 1998;9:233-43.
9. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-15.
10. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-61.
11. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44.
12. Selander K, Lehenkari P, Vaananen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994;55:368-75.
13. Marshall MJ, Wilson AS, Davie MW. Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts. J Bone Miner Res 1990;5:955-62.
14. Flanagan AM, Chambers TJ. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 1989;6:33-43.
15. Rowe DJ, Hausmann E. The effects of calcitonin and colchicine on the cellular response to diphosphonate. Br J Exp Pathol 1980;61:303-9.
16. Owens JM, Fuller K, Chambers TJ. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 1997;172: 79-86.
17. Felix R, Guenther HL, Fleisch H. The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 1984;36:108-13.
18. Rogers MJ, Watts DJ, Russell RG, Ji X, Xiong X, Blackburn GM, et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res 1994;9:1029-39.
19. Rogers MJ, Xiong X, Ji X, Monkkonen J, Russell RG, Williamson MP, et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm Res 1997;14:625-30.
20. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
21. Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970;6: 183-96.
22. Rowe DJ, Hays SJ. Inhibition of bone resorption by difluoromethylene diphosphonate in organ culture. Metab Bone Dis Rel Res 1983;5:13-6.
23. Rowe DJ, Etre LA, Lovdahl MJ, Pietrzyk DJ. Relationship between bisphosphonate concentration and osteoclast activity and viability. In Vitro Cell Dev Biol Anim 1999;35: 383-8.
24. Felix R, Fleisch H, Schenk R. Effect of halogenmethylenebisphosphonates on bone cells in culture and on bone resorption in vivo. Experientia 1986;42:302-4.
25. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
26. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Deroisy R, Lecart MP, et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone 1988;9:349-54.
27. Reginster JY. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992;13:351-4.
28. Bonjour JP, Ammann P, Barbier A, Caverzasio J, Rizzoli R. Tiludronate: bone pharmacology and safety. Bone 1995;17: 473S-7S.
29. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.
30. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-9.
31. Lowik CW, Van der Pluijm G, van der Wee-Pals LJ, Van Treslong-De Groot HB, Bijvoet OL. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988;3:185-92.
32. Papapoulos SE, Hoekman K, Lowik CW, Vermeij P, Bijvoet OLM. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 1989;4:775-81.
33. Van der Pluijm G, Binderup L, Bramm E, van der Wee-Pals L, DeGroot H, Binderup E, et al. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J Bone Miner Res 1992;7:981-6.
34. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Stein K, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11.
35. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-96.
36. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
37. Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone resorptive activity. Phosphorus, Sulfur Silicon 1996;109-110:217-20.
38. Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970;1:12-8.
39. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78.
40. Sunberg RJ, Ebetino FH, Mosher CT, Roof CF. Designing drugs for stronger bones. CHEMTECH 1991:304-9.
41. Ebetino FH, Jamieson LA. The design and synthesis of bone-active phosphinic acid analogues: I. The pyridylaminomethane phosphonoalkylphosphinates. Phosphorus Sulfur Silicon 1990;51/52:23-6.
42. van Beek ER, Lowik CW, Ebetino FH, Papapoulos SE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 1998;23:437-42.
43. Ebetino FH, Kaas SM, Crawford RJ. Bisphosphonates: molecular modelling, structure-activity relationships and the rational design of new analogs. Phosphorus, Sulfur Silicon 1993;76:151-4.
44. Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995;47:398-402.
45. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994;9:1875-82.
46. van Beek E, Lowik C, Que I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 1996;11:1492-7.
47. Brown RJ, van Beek E, Watts DJ, Lowik CWGM, Papapoulos SE. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Miner Res 1998;13:253-8.
48. Breuil V, Cosman F, Stein L, Hobert W, Nieves J, Shen V, et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998;13:1721-9.
49. Rowe EJ, Hausmann E. The alteration of osteoclast morphology by diphosphonates in bone organ culture. Calcif Tissue Res 1976;20:53-60.
50. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973;11: 196-214.
51. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-87.
52. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.
53. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamuru Y, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 1999;64: 219-23.
54. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment [In Process Citation]. Bone 1999;25:447-52.
55. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63:230-5.
56. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57: 3890-4.
57. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowick C, Papapoulos S, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
58. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
59. Miller SC, Jee WS. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 1979;193:439-62.
60. Plasmans CM, Jap PH, Kuijpers W, Slooff TJ. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int 1980;32:247-66.
61. Koshihara Y, Kodama S, Ishibashi H, Azuma Y, Ohta T, Karube S. Reversibility of alendronate-induced contraction in human osteoclast-like cells formed from bone marrow cells in culture. J Bone Miner Metab 1999;17:98-107.
62. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 1987;8:179-89.
63. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Thesing CW, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix. Bone Miner 1986;1:27-39.
64. Boonekamp PM, Lowik CWGM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Bijvoet OLM. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 1987;2:29-42.
65. Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 1994;26:95-107.
66. Hughes DE, McDonald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-5.
67. van Beek ER, Lowik CW, Papapoulos SE. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 1997;20:335-40.
68. Van der Pluijm G, Lowik CW, de Groot H, Alblas MJ, van der Wee-Pals LJ, Bijvoet OL, et al. Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. J Bone Miner Res 1991;6:1203-10.
69. Marshall MJ, Holt I, Davie MW. Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate. Calcif Tissue Int 1993;52:21-5.
70. Holt I, Marshall MJ, Davie MW. Pamidronate stimulates recruitment and decreases longevity of osteoclast nuclei in mice. Semin Arthitis Rheum 1994;23:263-4.
71. Endo Y, Nakamura M, Kikuchi T, Shinoda H, Takeda Y, Nitta Y, et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 1993; 52:248-54.
72. Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 1978;172:97-107.
73. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 1996;11:535-43.
74. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
75. Cecchini MG, Felix R, Fleisch H, Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987; 2:135-42.
76. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through mediation of osteoblasts. J Clin Invest 1993;91:2004-10.
77. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33.
78. Yu X, Scholler J, Foged NT. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996;19:339-45.
79. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9-14.
80. Chambers TJ. Diphosphonates inhibit bone resorption by macrophages in vitro. J Pathol 1980;132:255-62.
81. Mundy GR, Roodman GD. Osteoclast ontogeny and function. In: Peck WA, editor. Bone and mineral research annual V. Amsterdam: Elsevier, 1987:209-80.
82. Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 1990;5:1019-27.
83. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996;11:1482-91.
84. Coxon FP, Benford HL, Russell RGG, Rogers MJ. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998; 54:631-8.
85. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992;33:1657-63.
86. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung 1996;46:759-62.
87. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997;37:143-66.
88. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
89. Clark EA, King WG, Brugge JS, Symons M, Hynes RO. Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol 1998;142:573-86.
90. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
91. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
92. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, et al. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995;108:2285-92.
93. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MI. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
94. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995;96:2277-83.
95. Fong JH, Ingber DE. Modulation of adhesion-dependent cAMP signaling by echistatin and alendronate. Biochem Biophys Res Commun 1996;221:19-24.
96. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-8.
97. van Beek E, Lowik C, Van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates [In Process Citation]. J Bone Miner Res 1999;14:722-9.
98. Coxon FP, Luckman SP, Rogers MJ. Nitrogen-containing bisphosphonates prevent protein isoprenylation in osteoclasts by inhibiting IPP isomerase/FPP synthase [abstract]. J Bone Miner Res 1999;14:S197.
99. Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, et al. Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int 1998;63:143-7.
100. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.
101. Martin MB, Arnold W, Heath HT, Urbina JA, Oldfield E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun 1999;263:754-8.
102. Felix R, Fleisch H. Increase in fatty acid oxidation in calvaria cells cultured with diphosphonates. Biochem J 1981;196: 237-45.
103. Felix R, Graham R, Russell G, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976;429:429-38.
104. Klein G, Martin J-B, Satre M. Methylenediphosphonate, a metabolic poison in Dictyostelium discoideum. 31P NMR evidence for accumulation of adenosine 5′-(β,-γ-methylenetriphosphate) and diadenosine 5′,5‴-P1,P4-(P2,P3-methylenetetraphosphate). Biochemistry 1999;27:1897-901.
105. Rogers MJ, Russell RGG, Blackburn GM, Williamson MP, Watts DJ. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992;189:414-23.
106. Rogers MJ, Ji X, Russell RG, Blackburn GM, Williamson MP, Bayless AV, et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994;303:303-11.
107. Pelorgeas S, Martin JB, Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study. Biochem Pharmacol 1992;44:2157-63.
108. Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RGG, Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996; 224:863-9.
109. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67.
110. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Monkkonen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci App 1997;704:187-95.
111. 2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982;70:927-33.
112. Chatterjee D, Chakraborty M, Leit M, Neff L, Jamsa-Kellokumpu S, Fuchs R, et al. Sensitivity to vanadate and isoforms of subunits A and B distinguish the osteoclast proton pump from other vacuolar H+ ATPases. Proc Natl Acad Sci USA 1992;89:6257-61.
113. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989;245:855-7.
114. David P, Baron R. The vacuolar H+-ATPase: a potential target for drug development in bone diseases. Exp Opin Invest Drugs 1995;4:725-39.
115. David P, Nguyen H, Barbier A, Baron R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res 1996;11:1498-507.
116. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA 1996;93:3068-73.
117. Opas EE, Rutledge SJ, Golub E, Stern A, Zimola Z, Rodan GA, et al. Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol 1997;54:721-7.
118. Skorey K, Ly HD, Kelly J, Hammond M, Ramachandran C, Huang Z, et al. How does alendronate inhibit protein-tyrosine phosphatases? J Biol Chem 1997;272:22472-80.
119. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakaju S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997;20:399-404.